You are here

Investor Relations

Home

Jeffrey Leiden, Chairman, President and CEO

Date	Title and Summary
Toggle SummaryAug 20, 2019	FDA Accepts New Drug Application for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Combination Treatment -FDA Grants Priority Review of the application and sets a PDUFA target action date of March 19, 2020 - -Application supported by positive results from two global Phase 3 studies in people with cystic fibrosis ages 12 and older with one F508del mutation and one minimal function mutation and in General Business
Toggle SummaryJul 31, 2019	Vertex Reports Second-Quarter 2019 Financial Results - Product revenues of $940 million , a 25% increase compared to 2018 - - Company increases full-year 2019 total product revenue guidance to $3.6 to $3.7 billion - - Company advancing programs in 5 additional diseases beyond cystic fibrosis - BOSTON --(BUSINESS WIRE)--Jul. Financial
Toggle SummaryJul 25, 2019	Vertex Announces Dr. Jeffrey Leiden to Transition to Role of Executive Chairman, Effective April 1, 2020 and Dr. Reshma Kewalramani Appointed as New Chief Executive Officer BOSTON --(BUSINESS WIRE)--Jul. 25, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that its Board of Directors has approved the planned transition of Chairman, President and Chief Executive Officer Jeffrey Leiden , M.D., Ph.D, into the role of Executive Chairman of the General Business